How to Avoid Melanoma Recurrence Following Drug Treatment

Posted by Admin on April 12, 2012
Published in the New England Journal of Medicine, a recent study from The Institute of Cancer Research has demonstrated how to prevent the formation of new cancers when malignant melanoma patients receive treatment with drugs known as BRAF inhibitors.

Previously, doctors have noticed that between 15 and 30% of patients who received treatment with BRAF inhibitors developed another type of skin cancer known as cutaneous squamous cell carcinoma, which required surgical removal.

Co-senior author, Professor Richard Marais and his team examined squamous cell carcinoma tissue, which had been retrieved from 21 malignant melanoma patients who were treated with vemurafenib in a clinical trial. The researchers did testing on the tumor DNA to determine if there were known cancer-causing mutations and discovered that 60% of the samples had either KRAS or HRAS mutations.

Further testing revealed that the BRAF inhibitors do not directly trigger squamous cell carcinomas, but boost the growth of existing cancerous changes to the skin that were not yet exhibiting symptoms. The researchers also observed in mice that another type of drug, a MEK inhibitor, was capable of inhibiting the growth of these second tumors even in the presence of these BRAF drugs.

Marais explains the findings: "Around half of all patients with malignant melanoma have a mutation in their BRAF gene, and can be treated with BRAF-inhibiting drugs. However, between 15 and 30 per cent of the treated patients develop other skin tumors. By determining the mechanism by which these develop, we have been able to devise a strategy to prevent the second tumors without blocking the beneficial effects of the BRAF drugs. This may allow many more patients to benefit from these important drugs."

Cancer Research UK's senior science information manager, Dr Julie Sharp, concludes: "This research reveals a possible new approach to avoid the second cancers that affect some malignant melanoma patients taking BRAF inhibitors. The next stage will be to explore these results in more patients in clinical trials to see if this drug combination could treat the original cancer while preventing new cancers from forming."

Featured Specialities:
Featured Doctors:

The Eastchester Center for Cancer Care

Dr. Anthony Hoffman

2330 Eastchester Road
Bronx, NY 10469
Call: (718) 732-4000

NewYork-Presbyterian/Weill Cornell Medical Center

Dr. Fabrizio Michelassi

525 E 68th St # F-739
New York, New York 10065
Call: (212) 746-5145

Boston Children's Hospital

Dr. John Mulliken

300 Longwood Ave
Boston, MA 02115
Call: (617) 355-7686

Henry Ford Hospital

Dr. Kimberly Brown

2799 W Grand Blvd
Detroit, MI 48202
Call: (313) 556-8865

Johns Hopkins Medicine

Dr. Henry Brem

600 N. Wolfe Street
Baltimore, Maryland 21287
Call: 410-955-2248